Sientra (NASDAQ:SIEN) had its target price increased by Stifel Nicolaus from $21.00 to $25.00 in a research report report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.
Several other brokerages also recently issued reports on SIEN. Canaccord Genuity increased their price objective on shares of Sientra from $19.00 to $25.00 and gave the stock a buy rating in a research report on Wednesday. Zacks Investment Research downgraded shares of Sientra from a hold rating to a sell rating in a research report on Tuesday, August 7th. BidaskClub downgraded shares of Sientra from a strong-buy rating to a buy rating in a research report on Tuesday, July 31st. Craig Hallum assumed coverage on shares of Sientra in a research report on Monday, June 4th. They set a buy rating and a $23.00 price objective for the company. Finally, ValuEngine raised shares of Sientra from a buy rating to a strong-buy rating in a research report on Wednesday, May 2nd. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Sientra presently has a consensus rating of Buy and a consensus price target of $21.29.
NASDAQ:SIEN traded down $0.13 during trading hours on Wednesday, hitting $20.89. The stock had a trading volume of 278,337 shares, compared to its average volume of 355,514. Sientra has a one year low of $8.79 and a one year high of $26.79. The company has a quick ratio of 0.71, a current ratio of 3.06 and a debt-to-equity ratio of 0.27.
Sientra (NASDAQ:SIEN) last issued its quarterly earnings data on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.69) by ($0.04). Sientra had a negative return on equity of 151.47% and a negative net margin of 131.16%. The company had revenue of $17.55 million for the quarter, compared to the consensus estimate of $15.30 million. equities research analysts anticipate that Sientra will post -2.88 earnings per share for the current fiscal year.
Hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC bought a new position in Sientra in the second quarter valued at $20,375,000. BlackRock Inc. grew its position in Sientra by 94.3% in the second quarter. BlackRock Inc. now owns 1,490,587 shares of the medical instruments supplier’s stock valued at $29,081,000 after purchasing an additional 723,279 shares in the last quarter. Millennium Management LLC bought a new position in Sientra in the first quarter valued at $4,287,000. Columbus Circle Investors bought a new position in Sientra in the second quarter valued at $8,507,000. Finally, Cortina Asset Management LLC bought a new position in Sientra in the second quarter valued at $6,516,000. 60.47% of the stock is owned by institutional investors.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: How are Outstanding Shares Different from Authorized Shares?
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.